We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ACR market cap is 22.09M. The company's latest EPS is AUD -0.0026 and P/E is -30.77.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 4.7M | 1.4M | 5.12M | 5.09M | 11.81M |
| Operating Income | -8.92M | -11.93M | -12.47M | -9.6M | -334k |
| Net Income | -8.33M | -9.47M | -12.63M | -9.83M | -764k |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 24.43M | 17.84M | 23.33M | 14.3M | 13.29M |
| Total Liabilities | 2.5M | 4.99M | 4.86M | 5.21M | 4.59M |
| Total Equity | 21.94M | 12.85M | 18.47M | 9.09M | 8.7M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -9.94M | -8.53M | -11.41M | -8.82M | 703k |
| Investing | -380k | -254k | -102k | -465k | -119k |
| Financing | N/A | -159k | 17.58M | -155k | -183k |
| Market Cap | 22.09M |
| Price to Earnings Ratio | -30.77 |
| Price to Sales Ratio | 1.97 |
| Price to Cash Ratio | 3.74 |
| Price to Book Ratio | 2.67 |
| Dividend Yield | - |
| Shares Outstanding | 290.72M |
| Average Volume (1 week) | 602.73k |
| Average Volume (1 Month) | 377.59k |
| 52 Week Change | 72.73% |
| 52 Week High | 0.099 |
| 52 Week Low | 0.035 |
| Spread (Intraday) | 0 (5%) |
| Company Name | Acrux Limited |
| Address |
103-113 stanley street melbourne, victoria 3003 |
| Website | https://www.acrux.com.au |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
